MONTREAL Two new studies show that tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist (RA), significantly reduces cardiovascular risk in high-risk patients, including those undergoing percutaneous coronary intervention (PCI) and those with obesity undergoing transcatheter aortic valve replacement (TAVR)
Knowing when to expect changes, and when to expect improvement, prevents unnecessary anxiety and premature treatment abandonment
There are clinical trials evaluating if these GLP-1 and multi-agonists can address neurodegeneration, addiction, inflammation, and beyond
Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel
Muchos pacientes reportan una reduccin notable del hambre y los antojos dentro de los primeros das o semanas despus de iniciar el tratamiento, aunque esto vara individualmente